A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity
Latest Information Update: 27 Oct 2025
At a glance
- Drugs AZD-6234 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 27 Oct 2025 New trial record